Research Article

Impact of Some Pretreatment Clinical Factors on Artemether - Lumefantrine Treatment Failure in Malaria Patients attending some Health Care Centres in Kano State, Nigeria

Aminu, B.M.1*, Mukhtar, M.D.2
1 Department of Microbiology Bayero University, PMB 3011, Kano Nigeria.
2 Department of Science Laboratory Technology, School of Technology, Kano state polytechnic, Matan-fada Road, PMB 3348, Kano State, Nigeria
* Corresponding author: bintaaminu78@yahoo.com
Published: Dec, 2020
DOI: 10.67614/njm.2020.03d3ypxj
Pages: 5419-5427

Abstract

The efficacy of antimalarial drugs may be influenced by other factors independent of the parasite susceptibility to the drugs. This study aimed at evaluating the effect of some clinical factors on Arthemeter – Lumefantrine (AL) treatment failure in patients with uncomplicated malaria receiving care in selected community pharmaceutical shops and hospitals from Kano Municipal, Gwale, Tarauni and Kura Local Government Area. Four hundred (400) consenting patients with AL prescription were randomly selected for the study. Plasmodium falciparum positive subjects were confirmed by microscopic examination using Giemsa stained blood films techniques. Clinical and parasitological responses of the enrolled patients were evaluated using 28 days follow up according to WHO protocols for therapeutic efficacy. Structured questionnaire was used to record clinical details of each of the patients. Hematological parameters were assessed using automated hematology analyzer and blood group using antisera agglutination test kit. Among the 400 subjects enrolled, 220 (55%) completed the 28 days follow-up, out of which 170 (77.3%) had adequate clinical and parasitological response (ACPR) and 50 (22.7%) had treatment failure. The mean duration of symptoms before treatment, pre-treatment parasite density, parked cell volume(PCV),erythrocyte sedimentation rate(ESR) and white blood cell count (WBC) of patients with ACPR (4.3+2.1 days, 8,300+3,250/µl, 36+8.2%, 10.9+2.9mm/H and 5.8+2.5.1x109/L) were found to be significantly different (P

Keywords

Treatment failure Malaria Artemether-Lumefantrine clinical factors

References

  1. Adesola, O., Sangowawa, O.K., Sabulade, A.O., Folarkemi, A.A., Peter, E.O. and Olayemi, O.O. (2014). Factors Associated with a Poor Treatment Outcome Among Children Treated for Malaria in Ibadan Epidemiology Research International 10(1): Pp115.
  2. Aminu, B.M., Mukhtar, M.D. and Deeni, Y.Y. (2017): Assessment of Therapeutic Efficacy of ACT against Plasmodium falciparum Malaria in Kano and Katsina State, Nigeria. UMYU Journal of Microbiology Research: 2 (2): Pp 56 – 64.
  3. Cheesbrough, M. (2008): District Laboratory Practice Manual in Tropical Countries Cambridge University Press Pp 235 – 245.
  4. Degarege, A., Gebrezgi, M.Y. Ibanez, C.G and Wahlgren, M. (2019): Effect of the ABO Blood group on Susceptibility of Severe Malaria. A Systematic Review and Meta analysis: Blood Review 33:Pp101.
  5. Dorsey, G; Gasasira, A. F; Machekano, R; Kamya, M. R; Staedke, S. G; Hubbard, A; (2004) The impact of age, temperature, and parasite density on treatment outcomes from Antimalarial clinical trials in Kampala, Uganda. American journal of tropical medicine And hygiene 71(5).Pp531-536
  6. Federal Ministry of Health (FMOH). (2011): National policy on malaria diagnosis and treatmentAbuja.
  7. Gasasira, A.F., Kamya, M.R. Mebratula, T. (2008): High Risk Neutropenia in HIV Infected Children Following Treatment with Artesunate Plus Amodiaquine for Uncomplicated Malaria in Uganda: Clinical Infectious Disease 46: Pp 985 – 91.
  8. Happi, C., Gbotosho, G., Folann, O.O, Sawunmi, A, Hudson, T, Neil, M.O Milhouse, W., Wirth, D.F, and Oduola, A.M.J. (2008). Selection of Plasmodium falciparum Mdr1 in Asexual Stages and Gametocytes by Artemether – Lumefantrine in Nigerian children with Uncomplicated Falciparum Malaria. Journal of Antimicrobial Agents and Chemotherapy, 52: Pp 682 – 686.
  9. Humphreys, G.S., Marinopoulos, I. Ahmed, J, Whittyy, L.J. Mutabingwa, T.K., Sutherland, C.J and Hallet, R.L. (2007). Amodiaquine and Artemether Lumefantrine Select Distinct Alleles of the Plasmodium falciparum Mdr1 gene in Tanzanian Children Treated for Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy 51: Pp 991 – 997.
  10. O'flaherty, K.O, Maguire, J. Simpson, A.J and Fowkes F.J.I. (2017): Immunity as a Predictor of Antimalarial Treatment Failure: A Systematic Review Malaria Journal 16: Pp 158.
  11. Richmond, A., Edmond, A., James, P., Ellene, K.N. and Johnson, N.B. (2016): Relative Susceptibility of ABO Blood groups in Ghana. Advance in Haematology Volume 2016. Article ID 5368793, 4 pages. Hindawi.
  12. Sinclair, D. Zani, B., Donegan, S., Olliaro, P. (2009). Artemisin - based Combination Therapy for Treating Uncomplicated Malaria. Review cochrane Database System Review 8(1):Pp 220.
  13. Sisowath, C.J., Stromberg, A., Martensson, A., Msellem, C., Ohondo, A. and Gill, J.P. (2005). In vivo Selection of Pfmdr1 86N Coding Alleles by Artemether – Lumefantrine (Co-artem) Journal of Infectious Disease 191: Pp 1014 – 1017.
  14. Sutherland, C.J. Lundell, P., Sanders, W. Muwanguzi, J. and Van Schalkwyk, D.A. (2017): Pfk13 Independent Treatment Failure in four Imported Cases of P. falciparum Malaria with Artemether – Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapeucs. 61(3).
  15. Teddy, A.C., Moses, B., Diweni, P.D., Precious., O., Chioma, E.O and Joseph, O. (2013): Effects of Plasmodium falciparum on Haematological Parameters on Patients Treated with Artesunate in the Niger Delta of Nigeria. International Journal of Medical Sciences and Healthcare 1(12).
  16. Ukaga, C.N., Orji, C.N. Orogwi, S; Nwoke, B., Anosike, J.C., Udujih, O.S., Onyeka, A.and Awujo, N.C. (2006). Concomitant Bacteria in the Blood of Malaria Patients in Owerri, South Eastern Nigeria. Tanzania Health Research Bulletin 8(3).
  17. Vemula, S., Kataturu, B.U. Adappa, S., and Chakrapani, (216). Pretreatment Elevated ESR and R-reaction Protein as A Predictor of Malaria Complication J. Infect. Dev. Ceries 10(12): Pp 1332 – 1337.
  18. White, N. J (2018): Anaemia and Malaria. Malaria Journal 17(371) https://doi.org/10.1186/s12936-018-2509-9
  19. White, N. J (1997). Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial agent and chemotherapy 41:Pp1413-1432
  20. WHO (1996): Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated P. falciparum malaria in areas with Intense Transmission. World Health Organization https://apps.who.int/iris/handle/10665/63295/WHOMAL/96.1077:32P.
  21. WHO (2006): Guidelines for the Treatment of Malaria WHO press Geneva, Switzerland WHOHTM/MAL/2006.1108.
  22. WHO (2008): Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy. Genotyping to Identify Parasite Pop. https://www.int/iris/handle/10665/43824.
  23. WHO (2017): World Malaria Report, Global Malaria Program. Geneva WHO 2017 http://www.who.int/malam
  24. WHO (2019): Regional and Global Trends in Burden of Malaria Cases and death. World Malaria Report 2019. https://www.who.int.
  25. Yeka, A., Benek, K. Bakhaita, N. Staedke, S.G, Kamya, M.R, Talisuna, A., Kirrode, F., Nsobiya, S.L., Kilian, A., Slater, M., Reingold, A., Rosenthal, P.J., Wabire-mangin, F. and Dorsey, G. (2005): Artemisin Versus non Artemisin Combination Therapy for Uncomplicated Malaria Randomized Clinical Trials for Sites in Ugandan Public Library of Science Journal, 2(7): Pp190.
  26. Zongo, I, Dorsey, G., Rouamba, N. Dokomajilar, C., and Sere, Y., (2007): Randomized Comparison of Amodiaquine Plus Sulfadoxine – Pyrimethamine, Artemether and Dihydroartemisinin – Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Disease 45:Pp1453 – 1461.
  27. Zwang, J. Dorsey, G., Martensson, A., Alexandro, U., Ndiaye, J., Karema, C., Djimde, A., Phillippe, B., Sodiomon, B. and Olliaro, P. (2014): Plasmodium falciparum Clearance in Clinical Studies of Artesunate amodiaquine and Comparator Treatments in Sub – Saharan Africa. Malaria Journal 13:Pp 114.
How to Cite

B.M., A., & M.D., M. (2020). Impact of Some Pretreatment Clinical Factors on Artemether - Lumefantrine Treatment Failure in Malaria Patients attending some Health Care Centres in Kano State, Nigeria. Nigerian Journal of Microbiology, 34(2), 5419-5427. https://doi.org/10.67614/njm.2020.03d3ypxj

A. B.M., and M. M.D., "Impact of Some Pretreatment Clinical Factors on Artemether - Lumefantrine Treatment Failure in Malaria Patients attending some Health Care Centres in Kano State, Nigeria," Nigerian Journal of Microbiology, vol. 34, no. 2, pp. 5419-5427, December 2020. doi: 10.67614/njm.2020.03d3ypxj

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles